分组1 - Apellis Pharmaceuticals, Inc. reported a quarterly loss of $0.73 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.66, but an improvement from a loss of $1.50 per share a year ago [1] - The company posted revenues of $146.38 million for the quarter, missing the Zacks Consensus Estimate by 0.03%, but significantly up from $22.66 million year-over-year [1] - Over the last four quarters, Apellis has surpassed consensus revenue estimates three times, while it has only surpassed EPS estimates once [1] 分组2 - The stock has gained approximately 19.8% since the beginning of the year, outperforming the S&P 500's gain of 6.3% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $158.9 million, and for the current fiscal year, it is -$1.10 on revenues of $784.78 million [4] - The Medical - Biomedical and Genetics industry, to which Apellis belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the sector [5]

Fourth Quarter and Full Year 2023 Financial Results Conference Call Apellis Participants CEDRI C F RANCO I S, M. D. , Ph . D. Co-Founder, President & Chief Executive Officer ...

Core Insights - Apellis Pharmaceuticals reported a total revenue of $397 million for the full year 2023, with significant contributions from SYFOVRE® and EMPAVELI® [1][8] - The launch of SYFOVRE exceeded expectations, with over 160,000 doses distributed in 2023, and continued demand into 2024 [2][3] - The company is well-positioned for 2024, focusing on expanding SYFOVRE's reach and maximizing EMPAVELI's potential in PNH and C3G/IC-MPGN [2] Financial Performance - Total revenue for Q4 2023 was $146.4 million, a significant increase from $22.7 million in Q4 2022 [8] - For the full year 2023, total revenue was $396.6 million, compared to $75.4 million in 2022, marking a substantial growth [8] - The net loss for Q4 2023 was $88.5 million, while the full year net loss was $528.6 million, showing improvement compared to the previous year's losses [12] Product Highlights - SYFOVRE generated $275 million in revenue for the full year 2023, with Q4 revenue of $114.3 million [1][3] - EMPAVELI achieved $91 million in revenue for the full year 2023, with Q4 revenue of $24.4 million and a high patient compliance rate of 97% [4][8] - The company is advancing its pipeline, with topline data from the Phase 3 VALIANT study expected in mid-2024 [5] Research and Development - R&D expenses for Q4 2023 were $69.3 million, down from $99.4 million in Q4 2022, and full year R&D expenses were $354.4 million compared to $387.2 million in 2022 [10][11] - The company completed enrollment in the Phase 3 VALIANT study for systemic pegcetacoplan, with data expected in mid-2024 [5] Cash Position - As of December 31, 2023, Apellis had cash and cash equivalents of $351 million, down from $551.8 million in 2022 [7][8] - The company anticipates that its cash balance, along with expected revenue from SYFOVRE and EMPAVELI, will be sufficient to fund its projected operating expenses [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 | --- | --- | --- | |---------------------------------------------------------------------------------------|------------------ ...

Earnings Season Overview - The fourth-quarter 2023 earnings season is showing better-than-expected results, with total earnings for S&P 500 companies up 4.9% year-over-year on 3.4% higher revenues [1] - As of February 20, 402 S&P 500 companies reported earnings, with 78.6% exceeding EPS estimates and 64.4% surpassing revenue estimates [1] - Total earnings for the S&P 500 in Q4 2023 are projected to increase by 5.5% with 3.2% higher revenues, following a 3.8% earnings growth in Q3 2023 [1] Top Stock Picks - Five stocks are identified as likely to beat earnings this week, all carrying a Zacks Rank 2 (Buy) and a positive Earnings ESP [2] - Stocks with a Zacks Rank 3 (Hold) or better and a positive Earnings ESP have a 70% chance of beating earnings estimates [2] HEICO Corp. (HEI) - HEICO has seen improved demand for its aerospace products due to a recovery in commercial air travel, with an expected earnings growth rate of 11.4% for the current year [3] - The company has an Earnings ESP of +1.77% and has recorded earnings surprises in the last four quarters with an average beat of 7.8% [3] Constellation Energy Corp. (CEG) - CEG operates in multiple power regions and has an Earnings ESP of +1.47%, with a Zacks Consensus Estimate for current-year earnings improving by 0.7% [4] - The company has recorded earnings surprises in two of the last four quarters, averaging a beat of 37% [4] Inter Parfums Inc. (IPAR) - IPAR is benefiting from favorable trends in the fragrance market and plans to allocate 21% of its annual net sales to advertising and promotion [5] - The company has an Earnings ESP of +7.14% and an expected earnings growth rate of 8.6% for the current year, with an average earnings surprise of 45.7% over the last four quarters [5] Apellis Pharmaceuticals Inc. (APLS) - APLS is experiencing strong sales growth due to the demand for its products, including Syfovre and Empaveli [6] - The company has an Earnings ESP of +28.35% and an expected earnings growth rate of 75.1% for the current year, with a significant improvement in the Zacks Consensus Estimate by 20.3% [6] Vaxcyte Inc. (PCVX) - PCVX is focused on developing novel protein vaccines and has an Earnings ESP of +12.29%, with a 4.6% improvement in the Zacks Consensus Estimate over the last 30 days [7] - The company has recorded earnings surprises in two of the last four quarters, averaging a beat of 1.5% [7]

WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS) today announced that the company will participate in the following March investor conferences: TD Cowen 44th Annual Healthcare Conference: Fireside chat on Monday, March 4, 2024, at 2:10 p.m. ETOphthalmology Corporate Panel Discussion on Tuesday, March 5, 2024, at 9:10 a.m. ET Raymond James & Associates' 45th Annual Institutional Investors Conference: Fireside chat on Tuesday, March 5, 2024, at 11:00 a.m. ET The l ...

Investors are always looking for stocks that are poised to beat at earnings season and Apellis Pharmaceuticals, Inc. (APLS) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Apellis is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pre ...

Investors might want to bet on Apellis Pharmaceuticals, Inc. (APLS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Apellis Pharmaceuticals, Inc. (APLS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Apellis Pharmaceuticals, Inc. is one of 1071 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank gauges the ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the ...